Hookipa Pharma Inc., a NYC- and Vienna, Austria-based company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, completed a $37.4m (€33.2m) Series D financing.
The round was led by Redmile Group with participation from new investors Invus and Samsara BioCapital, as well as a number of current investors.
Led by Joern Aldag, Chief Executive Officer, Hookipa Pharma is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.
Its proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies.
The company intends to use the funds to progress the clinical development of its lead development programs, HB-101, a prophylactic cytomegalovirus vaccine candidate, currently in a Phase 2 clinical trial in patients awaiting kidney transplantation as well as HB-201 and HB-202, its lead oncology product candidates, in development for the treatment of human papillomavirus-positive cancers.
In addition, Hookipa plans to apply its arenavirus platform to develop additional novel immuno-oncology product candidates.